Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma.

Koelzer VH, Gisler A, Hanhart JC, Griss J, Wagner SN, Willi N, Cathomas G, Sachs M, Kempf W, Thommen DS, Mertz KD.

Histopathology. 2018 Sep;73(3):397-406. doi: 10.1111/his.13528. Epub 2018 Jun 5.

PMID:
29660160
2.

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.

Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN.

Nat Commun. 2017 Sep 19;8(1):607. doi: 10.1038/s41467-017-00452-4.

3.

A slow-cycling subpopulation of melanoma cells with highly invasive properties.

Perego M, Maurer M, Wang JX, Shaffer S, Müller AC, Parapatics K, Li L, Hristova D, Shin S, Keeney F, Liu S, Xu X, Raj A, Jensen JK, Bennett KL, Wagner SN, Somasundaram R, Herlyn M.

Oncogene. 2018 Jan 18;37(3):302-312. doi: 10.1038/onc.2017.341. Epub 2017 Sep 18.

4.

Signal Sequence Receptor 2 is required for survival of human melanoma cells as part of an unfolded protein response to endoplasmic reticulum stress.

Garg B, Pathria G, Wagner C, Maurer M, Wagner SN.

Mutagenesis. 2016 Sep;31(5):573-82. doi: 10.1093/mutage/gew023. Epub 2016 May 14.

PMID:
27180333
5.

Dual c-Jun N-terminal kinase-cyclin D1 and extracellular signal-related kinase-c-Jun disjunction in human melanoma.

Pathria G, Garg B, Garg K, Wagner C, Wagner SN.

Br J Dermatol. 2016 Dec;175(6):1221-1231. doi: 10.1111/bjd.14713. Epub 2016 Sep 20.

PMID:
27145925
6.

Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.

Garg K, Maurer M, Griss J, Brüggen MC, Wolf IH, Wagner C, Willi N, Mertz KD, Wagner SN.

Hum Pathol. 2016 Aug;54:157-64. doi: 10.1016/j.humpath.2016.03.022. Epub 2016 Apr 21.

PMID:
27107457
7.

Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.

Pathria G, Garg B, Borgdorff V, Garg K, Wagner C, Superti-Furga G, Wagner SN.

Cell Death Dis. 2016 Mar 10;7:e2135. doi: 10.1038/cddis.2015.369.

8.

The role of tumor microenvironment in melanoma therapy resistance.

Somasundaram R, Herlyn M, Wagner SN.

Melanoma Manag. 2016 Mar;3(1):23-32. doi: 10.2217/mmt.15.37. Epub 2016 Feb 12. Review.

9.

RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export.

Pathria G, Garg B, Wagner C, Garg K, Gschaider M, Jalili A, Wagner SN.

J Invest Dermatol. 2016 Jan;136(1):264-74. doi: 10.1038/JID.2015.401.

10.

A Peptide to Reduce Pulmonary Edema in a Rat Model of Lung Transplantation.

Schossleitner K, Habertheuer A, Finsterwalder R, Friedl HP, Rauscher S, Gröger M, Kocher A, Wagner C, Wagner SN, Fischer G, Schultz MJ, Wiedemann D, Petzelbauer P.

PLoS One. 2015 Nov 4;10(11):e0142115. doi: 10.1371/journal.pone.0142115. eCollection 2015.

11.

RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export.

Pathria G, Garg B, Wagner C, Garg K, Gschaider M, Jalili A, Wagner SN.

J Invest Dermatol. 2015 Oct 8. doi: 10.1038/jid.2015.401. [Epub ahead of print]

PMID:
26447822
12.

Comprehensive comparative and semiquantitative proteome of a very low number of native and matched epstein-barr-virus-transformed B lymphocytes infiltrating human melanoma.

Maurer M, Müller AC, Parapatics K, Pickl WF, Wagner C, Rudashevskaya EL, Breitwieser FP, Colinge J, Garg K, Griss J, Bennett KL, Wagner SN.

J Proteome Res. 2014 Jun 6;13(6):2830-45. doi: 10.1021/pr401270y. Epub 2014 May 6.

PMID:
24803318
13.

MTSS1 is a metastasis driver in a subset of human melanomas.

Mertz KD, Pathria G, Wagner C, Saarikangas J, Sboner A, Romanov J, Gschaider M, Lenz F, Neumann F, Schreiner W, Nemethova M, Glassmann A, Lappalainen P, Stingl G, Small JV, Fink D, Chin L, Wagner SN.

Nat Commun. 2014 Mar 17;5:3465. doi: 10.1038/ncomms4465.

PMID:
24632752
14.

NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.

Jalili A, Mertz KD, Romanov J, Wagner C, Kalthoff F, Stuetz A, Pathria G, Gschaider M, Stingl G, Wagner SN.

PLoS One. 2013 Jul 30;8(7):e69064. doi: 10.1371/journal.pone.0069064. Print 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/ddd22094-5d8d-43ef-ad81-b95afe392ec7.

15.

A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF.

Borgdorff V, Rix U, Winter GE, Gridling M, Müller AC, Breitwieser FP, Wagner C, Colinge J, Bennett KL, Superti-Furga G, Wagner SN.

Oncogene. 2014 May 8;33(19):2531-9. doi: 10.1038/onc.2013.185. Epub 2013 Jun 3.

PMID:
23728343
16.

Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence.

Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, Zhang R.

Cell Rep. 2013 Apr 25;3(4):1252-65. doi: 10.1016/j.celrep.2013.03.004. Epub 2013 Apr 4.

17.

Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches.

Maurer M, Somasundaram R, Herlyn M, Wagner SN.

Oncoimmunology. 2012 Nov 1;1(8):1454-1456.

18.

Combining filter-aided sample preparation and pseudoshotgun technology to profile the proteome of a low number of early passage human melanoma cells.

Maurer M, Müller AC, Wagner C, Huber ML, Rudashevskaya EL, Wagner SN, Bennett KL.

J Proteome Res. 2013 Feb 1;12(2):1040-8. doi: 10.1021/pr301009u. Epub 2012 Dec 24.

PMID:
23214492
19.

An attempt at a molecular prediction of metastasis in patients with primary cutaneous melanoma.

Gschaider M, Neumann F, Peters B, Lenz F, Cibena M, Goiser M, Wolf I, Wenzel J, Mauch C, Schreiner W, Wagner SN.

PLoS One. 2012;7(11):e49865. doi: 10.1371/journal.pone.0049865. Epub 2012 Nov 14.

20.

Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.

Jalili A, Wagner C, Pashenkov M, Pathria G, Mertz KD, Widlund HR, Lupien M, Brunet JP, Golub TR, Stingl G, Fisher DE, Ramaswamy S, Wagner SN.

J Natl Cancer Inst. 2012 Nov 7;104(21):1673-9. doi: 10.1093/jnci/djs373. Epub 2012 Sep 20.

21.

Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways.

Pathria G, Wagner C, Wagner SN.

J Invest Dermatol. 2012 Dec;132(12):2780-90. doi: 10.1038/jid.2012.233. Epub 2012 Jul 26.

22.

A landscape of driver mutations in melanoma.

Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L.

Cell. 2012 Jul 20;150(2):251-63. doi: 10.1016/j.cell.2012.06.024.

23.

Melanoma genome sequencing reveals frequent PREX2 mutations.

Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner SN, Lander ES, Getz G, Chin L, Garraway LA.

Nature. 2012 May 9;485(7399):502-6. doi: 10.1038/nature11071.

24.

Targeting CD20 in melanoma patients at high risk of disease recurrence.

Pinc A, Somasundaram R, Wagner C, Hörmann M, Karanikas G, Jalili A, Bauer W, Brunner P, Grabmeier-Pfistershammer K, Gschaider M, Lai CY, Hsu MY, Herlyn M, Stingl G, Wagner SN.

Mol Ther. 2012 May;20(5):1056-62. doi: 10.1038/mt.2012.27. Epub 2012 Feb 21.

25.

γδ T-cell lymphoma mimicking Sézary syndrome.

Bauer W, Spazierer D, Klein I, Stary G, Wöhrl S, Wagner SN, Knobler R, Müllauer L, Stingl G.

Acta Derm Venereol. 2012 Mar;92(2):166-8. doi: 10.2340/00015555-1195. No abstract available.

26.

Polo-like kinase 1 is a potential therapeutic target in human melanoma.

Jalili A, Moser A, Pashenkov M, Wagner C, Pathria G, Borgdorff V, Gschaider M, Stingl G, Ramaswamy S, Wagner SN.

J Invest Dermatol. 2011 Sep;131(9):1886-95. doi: 10.1038/jid.2011.136. Epub 2011 Jun 9.

27.

Integrative genome comparison of primary and metastatic melanomas.

Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, Scott KL, Kwong LN, Xiao Y, Cordon-Cardo C, Granter SR, Ramaswamy S, Golub T, Duncan LM, Wagner SN, Brennan C, Chin L.

PLoS One. 2010 May 24;5(5):e10770. doi: 10.1371/journal.pone.0010770.

28.

Induction of targeted cell migration by cutaneous administration of a DNA vector encoding a biologically active chemokine CCL21.

Jalili A, Pashenkov M, Kriehuber E, Wagner C, Nakano H, Stingl G, Wagner SN.

J Invest Dermatol. 2010 Jun;130(6):1611-23. doi: 10.1038/jid.2010.31. Epub 2010 Feb 25.

29.

Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.

Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN.

J Dtsch Dermatol Ges. 2008 Dec;6(12):1066-9. doi: 10.1111/j.1610-0387.2008.06861.x. English, German.

PMID:
19138272
30.

Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group.

Eigentler TK, Radny P, Hauschild A, Gutzmer R, Linse R, Pföhler C, Wagner SN, Schadendorf D, Ellwanger U, Garbe C; German Dermatologic Cooperative Oncology Group.

Melanoma Res. 2008 Oct;18(5):353-8. doi: 10.1097/CMR.0b013e32830e3936.

PMID:
18781134
31.

Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases.

Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, Wagner SN, Ramaswamy S, Mesirov JP, Hynes RO.

Mol Cancer Res. 2008 May;6(5):760-9. doi: 10.1158/1541-7786.MCR-07-0344.

32.

Growth factors and oncogenes as targets in melanoma: lost in translation?

Kwong L, Chin L, Wagner SN.

Adv Dermatol. 2007;23:99-129. Review. No abstract available.

33.

Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.

Pashenkov M, Goëss G, Wagner C, Hörmann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN.

J Clin Oncol. 2006 Dec 20;24(36):5716-24.

PMID:
17179105
34.

Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene.

Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, Brennan C, Hahn WC, Cordon-Cardo C, Wagner SN, Flotte TJ, Duncan LM, Granter SR, Chin L.

Cell. 2006 Jun 30;125(7):1269-81.

35.

EMPACT syndrome.

Wöhrl S, Loewe R, Pickl WF, Stingl G, Wagner SN.

J Dtsch Dermatol Ges. 2005 Jan;3(1):39-43.

PMID:
16353748
36.

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR.

Nature. 2005 Jul 7;436(7047):117-22.

37.

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).

Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B, Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G, Schuler-Thurner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J, Enk A, Huber C, Wölfel T.

Cancer Immunol Immunother. 2005 May;54(5):453-67. Epub 2004 Dec 31.

PMID:
15627214
38.

Melanoma--new developments in diagnosis and therapy.

Schneeberger A, Wagner SN.

Cancer Chemother Biol Response Modif. 2003;21:609-36. Review. No abstract available.

PMID:
15338766
39.

CpG motifs are efficient adjuvants for DNA cancer vaccines.

Schneeberger A, Wagner C, Zemann A, Lührs P, Kutil R, Goos M, Stingl G, Wagner SN.

J Invest Dermatol. 2004 Aug;123(2):371-9.

40.

[Surgical therapy of malignant melanoma of the external ear].

Dost P, Lehnerdt G, Kling R, Wagner SN.

HNO. 2004 Jan;52(1):33-7. Epub 2003 Jun 19. German.

PMID:
14740112
41.

Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma.

Dissemond J, Busch M, Kothen T, Mörs J, Weimann TK, Lindeke A, Goos M, Wagner SN.

Cancer Lett. 2004 Jan 20;203(2):225-31.

PMID:
14732231
42.

Activated neutrophils exert antitumor activity against human melanoma cells: reactive oxygen species-induced mechanisms and their modulation by granulocyte-macrophage-colony-stimulating factor.

Dissemond J, Weimann TK, Schneider LA, Schneeberger A, Scharffetter-Kochanek K, Goos M, Wagner SN.

J Invest Dermatol. 2003 Oct;121(4):936-8. No abstract available.

43.

Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression.

Tuve S, Wagner SN, Schittek B, Pützer BM.

Int J Cancer. 2004 Jan 1;108(1):162-6.

44.

Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression.

Dissemond J, Goette P, Moers J, Lindeke A, Goos M, Ferrone S, Wagner SN.

Melanoma Res. 2003 Aug;13(4):371-7.

PMID:
12883363
45.

Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression.

Dissemond J, Götte P, Mörs J, Lindeke A, Goos M, Ferrone S, Wagner SN.

Melanoma Res. 2003 Jun;13(3):253-8.

PMID:
12777979
46.

Venous leg ulcers in a patient with Klinefelter's syndrome and increased activity of plasminogen activator inhibitor-1.

Dissemond J, Schultewolter T, Brauns TC, Goos M, Wagner SN.

Acta Derm Venereol. 2003;83(2):149-50. No abstract available.

48.

Downregulation of tapasin expression in progressive human malignant melanoma.

Dissemond J, Kothen T, Mörs J, Weimann TK, Lindeke A, Goos M, Wagner SN.

Arch Dermatol Res. 2003 Jun;295(2):43-9. Epub 2003 Mar 28. Review.

PMID:
12682852
49.

[The role of oxidative stress in the pathogenesis and therapy of chronic wounds].

Dissemond J, Goos M, Wagner SN.

Hautarzt. 2002 Nov;53(11):718-23. Review. German.

PMID:
12402133
50.

Induction of specific immune responses by polycation-based vaccines.

Lührs P, Schmidt W, Kutil R, Buschle M, Wagner SN, Stingl G, Schneeberger A.

J Immunol. 2002 Nov 1;169(9):5217-26.

Supplemental Content

Loading ...
Support Center